Cyclacel Pharmaceuticals (CYCC)

Cyclacel Pharmaceuticals (CYCC) Stock Price & Analysis


CYCC Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.50 - $2.41
Previous Close$0.68
Average Volume (3M)52.03K
Market Cap
Enterprise Value$1.66M
Total Cash (Recent Filing)$11.44M
Total Debt (Recent Filing)$80.00K
Price to Earnings (P/E)-0.3
Aug 09, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.94
Shares Outstanding12,539,189
10 Day Avg. Volume28,240
30 Day Avg. Volume52,034
Standard Deviation0.24
Financial Highlights & Ratios
Price to Book (P/B)1.67
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.06
Price Target Upside1093.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Cyclacel Pharmaceuticals’s price range in the past 12 months?
Cyclacel Pharmaceuticals lowest stock price was $0.50 and its highest was $2.41 in the past 12 months.
    What is Cyclacel Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Cyclacel Pharmaceuticals’s upcoming earnings report date?
    Cyclacel Pharmaceuticals’s upcoming earnings report date is Aug 09, 2023 which is in 60 days.
      How were Cyclacel Pharmaceuticals’s earnings last quarter?
      Cyclacel Pharmaceuticals released its earnings results on May 11, 2023. The company reported -$0.47 earnings per share for the quarter, beating the consensus estimate of -$0.663 by $0.193.
        Is Cyclacel Pharmaceuticals overvalued?
        According to Wall Street analysts Cyclacel Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Cyclacel Pharmaceuticals pay dividends?
          Cyclacel Pharmaceuticals does not currently pay dividends.
          What is Cyclacel Pharmaceuticals’s EPS estimate?
          Cyclacel Pharmaceuticals’s EPS estimate is -$0.53.
            How many shares outstanding does Cyclacel Pharmaceuticals have?
            Cyclacel Pharmaceuticals has 12,539,189 shares outstanding.
              What happened to Cyclacel Pharmaceuticals’s price movement after its last earnings report?
              Cyclacel Pharmaceuticals reported an EPS of -$0.47 in its last earnings report, beating expectations of -$0.663. Following the earnings report the stock price went down -1.786%.
                Which hedge fund is a major shareholder of Cyclacel Pharmaceuticals?
                Currently, no hedge funds are holding shares in CYCC


                Cyclacel Pharmaceuticals Stock Smart Score

                This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                Learn more about TipRanks Smart Score

                Company Description

                Cyclacel Pharmaceuticals

                Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. The company builds a diversified biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.


                Top 5 ETFs holding CYCC

                Market Value
                Smart Score
                iShares Core S&P Total U.S. Stock Market ETF
                Up to five ETFs with an Outperform Smart Score that hold CYCC. The ETFs are listed according to market value of CYCC within the ETF


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Citius Pharmaceuticals
                Bio-Path Holdings

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis